Lillys Mounjaro (Tirzepatide), a GIP/GLP-1 Dual Agonist, Demonstrated Cardiovascular Protection in Landmark Head-to-Head Trial, Reinforcing Its Benefit in Patients with Type 2 Diabetes and Heart Disease (Eli Lilly and Company, accessed 19 August 2025)
Some people find that lowering the dose allows their body to adjust without experiencing strong side effects
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward based on therapeutic response and tolerability
State-licensed pharmacies operating under Section 503A had until February 18, 2025, to wind down production
They can change your treatment plan to help you get the best results
Monitoring: Track weight weekly (same day, same time, same conditions)